Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    23andMe Holding Co. (ME) Insider Trading Activity

    Healthcare • Diagnostics & Research • 560 employees

    23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California.

    Total Value

    $186,234.09

    Total Shares

    5,292,558

    Average Trade Value

    $10,954.95

    Most Active Insider

    Montgomery Rice Valerie Md

    Total Activity: $75,000

    Largest Single Transaction

    $67,500

    by Chung Patrick S on Aug 26, 2024

    30-Day Activity

    1 Transaction

    Volume: 5,279 shares
    Value: $16,629

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Chief Financial Actng Ofcr
    Officer
    Nov 20, 2024 5,279 $16,629 102,122 (-5.2%) Payment of Exercise Price
    Director
    Aug 26, 2024 658,485 $0 904,291 (+72.8%) Grant
    Director
    Aug 26, 2024 658,485 $0 959,906 (+68.6%) Grant
    Director
    Aug 26, 2024 179,586 $60,000 483,526 (+37.1%) Grant
    Director
    Aug 26, 2024 658,485 $0 895,961 (+73.5%) Grant
    Director
    Aug 26, 2024 202,035 $67,500 1,161,941 (+17.4%) Grant
    Director
    Aug 26, 2024 658,485 $0 658,485 (+100.0%) Grant
    Director
    Aug 26, 2024 149,655 $50,000 1,203,204 (+12.4%) Grant
    Director
    Aug 26, 2024 194,552 $65,000 1,207,918 (+16.1%) Grant
    Director
    Aug 26, 2024 658,485 $0 981,217 (+67.1%) Grant
    Director
    Aug 26, 2024 658,485 $0 1,013,366 (+65.0%) Grant
    Director
    Aug 26, 2024 658,485 $0 1,053,549 (+62.5%) Grant
    Chief Financial Actng Ofcr
    Officer
    Aug 20, 2024 110,388 $39,243 2,148,002 (-5.1%) Payment of Exercise Price
    Head of Therapeutics Discovery
    Officer
    Aug 20, 2024 57,365 $20,393 573,069 (-10.0%) Payment of Exercise Price
    Director
    Jun 30, 2024 57,515 $10,000 395,064 (+14.6%) Grant
    Director
    Jun 30, 2024 15,337 $10,000 354,881 (+4.3%) Grant
    Director
    Jun 30, 2024 57,515 $0 322,732 (+17.8%) Grant